Variant position: 301 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 933 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ALVEQDAPMAPGRSPLATTV MDFIHVPILPLNHALLAARTR
Gorilla ALVEQDAPMAPGRSPLATTV MDFIHVPILPLNHALLAARTR
Chimpanzee ALVEQDAPMAPXRSPLATTM MDFIHVPILPLNHALLAARTR
Mouse SL-EQDSPIAPGRSPLATTV VDFIHVPILPLNHALLAARTR
Rat SL-EQDAPVAPGRSPLATTV VDFIHVPILPLNHALLAARTR
Rabbit SLAEQDAPVAPGRSPLATSV VDFIHVPILPLNHAFLATRTR
Chicken --------VEPGAGQ----- -DYLHVPILPLNSAFLASRTR
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 933 Progesterone receptor
1 – 566 Modulating, Pro-Rich
165 – 305 Mediates transcriptional transrepression (in isoform A)
294 – 294 Phosphoserine; by MAPK1
1 – 594 Missing. In isoform 3.
17 – 635 Missing. In isoform 4.
294 – 294 S -> A. No effect on interaction with CUEDC2. Impaired progesterone-induced transcriptional activity. No CUEDC2- nor progestin-mediated protein degradation. No change in sumoylation; when associated with A-344 and A-345.
294 – 294 S -> D. Decreases protein stability and increases progesterone-induced transcriptional activity.
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-50; VAL-120; LEU-186; ARG-301; THR-344; SER-444; LEU-529; PRO-536; VAL-651 AND LEU-865;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.